<DOC>
	<DOC>NCT03014895</DOC>
	<brief_summary>The study (E3112/CP1) is a single-center, randomized, double-blind, placebo-controlled, single intravenous ascending dose study conducted in Japanese healthy adult males to evaluate the pharmacokinetics (PK), safety, and immunogenicity of E3112 following a single intravenous dose of E3112.</brief_summary>
	<brief_title>A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects</brief_title>
	<detailed_description />
	<criteria>Main Nonsmoking, Japanese, male participants, ≥20 and &lt;45 years old at the time of obtaining informed consent Have a Body Mass Index (BMI) ≥18.5 and &lt;25.0 kilograms per meters squared (kg/m^2) at Screening Able to provide written informed consent of their free will Males who were given a full explanation of all the requirements of the protocol, and are willing and able to comply with them Main Male and his partner who do not agree to use a highly effective method of contraception throughout the entire study period, if he has reproductive capacity Male who had or has any malignant tumor, lymphoma, leukaemia, or lymphoproliferative disorders. Clinically significant illness that required medical treatment within 8 weeks or a clinically significant infection within 4 weeks prior to dosing. Evidence of disease that may influence the outcome of the study within 4 weeks prior to dosing Any history of surgical treatment that may affect pharmacokinetic (PK) profiles of study drug at Screening Any suspected clinically abnormal symptom or organ impairment that require medical treatment at Screening or Baseline Receipt of vaccination within 4 weeks prior to dosing History of drug or alcohol dependency or abuse prior to Screening Intake of caffeinated beverages or food within 72 hours prior to dosing Use of prescription drugs within 4 weeks prior to dosing Intake of overthecounter (OTC) medications within 2 weeks prior to dosing Male who is currently being enrolled in another clinical study or used any investigational drug or device in another clinical study within 16 weeks prior to dosing Male who underwent a blood transfusion within 12 weeks prior to dosing, who donate 400 milliliters (mL) or more of whole blood within 12 weeks prior to dosing, who donate 200 mL or more of whole blood within 4 weeks prior to dosing, or who made a component donation within 2 weeks prior to dosing</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>E3112</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Japanese</keyword>
</DOC>